A British maker of medical technology that helps surgeons and doctors mend the human body, from hip and knee implants and surgical robotics to wound-care dressings used in hospitals worldwide. It began in 1856 when pharmacist Thomas James Smith opened a small chemist shop in Hull, England, selling cod liver oil to local hospitals. The "Nephew" in its name arrived in 1896, when his nephew Horatio Nelson Smith joined and steered the business toward bandages and surgical dressings — a change that shaped everything that followed.
Bank of America discloses 2.89% voting rights in Smith & Nephew plc
The position comprises 2.461592% direct voting rights in shares and 0.427242% through financial instruments.
Show detailsHide details
Bank of America Corporation crossed a voting rights threshold on 19-Aug-2026, holding 2.888834% of total voting rights in Smith & Nephew plc.
Financial instruments include a right to recall (0.030791%) and cash-settled swaps and a put option (0.396451%).
The notification was made on 20-Aug-2026 and filed with the SEC on 21-Aug-2026.
The holdings are managed through controlled undertakings including Bank of America, National Association, BofA Securities, Inc., and U.S. Trust Co of Delaware.
Smith & Nephew files Form 6-K with interim financial report for period ended June 27, 2026
The report covers segment results for Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management, with breakdowns by established and emerging markets.
Show detailsHide details
The Form 6-K, filed August 14, 2026, contains the company's interim financial statements for the half-year ended June 27, 2026.
The filing includes details on share buyback programmes initiated in May 2026 and August 2025, and a euro corporate bond issued in 2026.
Financial disclosures include fair value measurements for financial instruments, derivatives, and acquisition consideration liabilities.
The report also addresses provisions for metal-on-metal hip claims and the acquisition of Integrity Orthopaedics.
Cevian Capital II GP Limited increases stake in Smith & Nephew to 14.21%
Cevian Capital II GP Limited crossed a voting rights threshold on 07-Aug-2026, now holding 14.214414% of Smith & Nephew's voting rights.
Show detailsHide details
The aggregate holding increased from 14.010786% to 14.214414%, with 119,179,419 voting rights attached to shares.
The increase was driven by a rise in Cevian Capital II Master Fund L.P.'s stake to 13.014856% and Cevian Capital II Co-Investment - Series P L.P.'s stake to 1.199558%.
Shares are held by Aurora Nominees Limited as nominee on behalf of UBS AG as custodian.
The notification was made for transparency purposes; no new notification threshold was crossed.
Smith & Nephew PDMR Rohit Kashyap vests 23,202 shares under 2023 performance award
On 12 August 2026, Smith & Nephew plc received notification of share transactions by PDMR Rohit Kashyap, President of Advanced Wound Management and Global Commercial Operations.
Show detailsHide details
The transactions involved the vesting of 2023 performance share awards under the Smith & Nephew Global Share Plan 2020, with shares sold to cover tax liabilities.
Kashyap acquired 23,202 ordinary shares (including dividend equivalents) at a price of £11.096264 per share; 9,163 shares were sold and 14,039 retained.
The transactions occurred on the London Stock Exchange (XLON) on 12 August 2026.
The announcement was made under the UK Market Abuse Regulation.
Smith+Nephew H1 2026 revenue up 4.6% reported, trading profit up 8.1% to $566M
Trading profit rose 8.1% to $566 million, with margin up 60bps to 18.3%, driven by efficiency savings.
Show detailsHide details
H1 2026 revenue was $3,097 million, up 4.6% reported and 2.3% underlying, with a 230bps FX tailwind.
Adjusted EPS (EPSA) increased 11.0% to 47.7 cents; basic EPS rose 6.2% to 35.6 cents.
Full-year revenue growth guidance reduced from ~6% to ~4%, but trading profit, free cash flow, and ROIC guidance unchanged.
Interim dividend increased 4.0% to 15.6 cents per share; $500 million share buyback announced in May, $216 million settled as of August 3.
Q2 revenue was $1,597 million, up 1.6% underlying, with strength in Sports Medicine offset by softness in US Orthopaedics and Advanced Wound Bioactives.